April 19, 2024

• 

[THE INVESTOR] Chongkundang Pharmaceutical will continue to grow steadily, said HMC Investment Securities on June 16, raising the target price to 143,000 won (US$125.76) from 135,000 won.

The upturn in its key imported drugs, including diabetes treatment Januvia and neuroprotective drug Gliatilin, will bolster its solid growth, said analyst Kang Yang-gu. Its own incrementally modified drugs, such as Lipilou for hyperlipidemia, and Dilatrend and Telminuvo for hypertension, are faring well and will propel the improvement, added the analyst. 

As its own diabetes therapy Duvie has been proved safe and effective by American Diabetes Association, subscription in domestic market will continue to rise. It will serve as a momentum to expand overseas, added the analyst.

The pharmaceutical company’s revenue in the second quarter will rise 4.3 percent on-year to 214.6 billion won and operating profit will surge 44.1 percent to 15.2 billion won, estimated Kang.

By Hwang You-mee (glamazon@heraldcorp.com)